Sarcoma, Synovial

9 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms, Sarcoma

Treatments and conditions

Sarcoma, Synovial
Treatment and conditionWhere it standsTrials
Definitive radiotherapy for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peptide vaccine IPX for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Quality of Life + Functional outcome + preoperative for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.